AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19622294 — intervention group
Group type: COMPARATOR
Intervention: Surgery group
Number of subjects: 59
Study 19622294 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib plus surgery group
Number of subjects: 59
Study 19622294 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy subjects)
Number of subjects: 59
Study 16671485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrostatic shunt with an opening pressure of 50 mmH2O
Number of subjects: 123
Study 16671485 — intervention group
Group type: COMPARATOR
Intervention: Hydrostatic shunt with an opening pressure of 100 mmH2O
Number of subjects: 123
Study 16671485 — intervention group
Group type: COMPARATOR
Intervention: Hydrostatic shunt with an opening pressure of 130 mmH2O
Number of subjects: 123
Study 15273527 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training program
Number of subjects: 44
Study 15273527 — intervention group
Group type: COMPARATOR
Intervention: Basic exercise training program
Number of subjects: 44
Study 11510392 — intervention group
Group type: EXPERIMENTAL
Intervention: Water drops at body temperature, followed by a series of syringing attempts after 15 minutes.
Number of subjects: 42
Study 11510392 — intervention group
Group type: COMPARATOR
Intervention: Oil as a dispersant for three days, followed by a series of syringing attempts after three days.
Number of subjects: 42
Study 1334820 — intervention group
Group type: EXPERIMENTAL
Intervention: Double data entry (DE)
Number of subjects: 42278
Study 1334820 — intervention group
Group type: COMPARATOR
Intervention: Single entry (SE)
Number of subjects: 42278
Study 6373303 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide
Number of subjects: 119
Study 6373303 — intervention group
Group type: COMPARATOR
Intervention: 100 mg atenolol
Number of subjects: 119
Study 6373303 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to atenolol after non-response to hydrochlorothiazide
Number of subjects: 119
Study 6373303 — intervention group
Group type: COMPARATOR
Intervention: Switch to hydrochlorothiazide after non-response to atenolol
Number of subjects: 119
Study 6373303 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy for non-responders
Number of subjects: 119
Study 6373303 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 119
Study 31801592 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed evolution of ZfQQR zinc finger variants with optimized linker sequences
Number of subjects: 0
Study 31801592 — intervention group
Group type: COMPARATOR
Intervention: Original ZfQQR zinc finger
Number of subjects: 0
Study 30558396 — intervention group
Group type: EXPERIMENTAL
Intervention: Central European Diet (CED)
Number of subjects: 144
Study 30558396 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean Diet (MED)
Number of subjects: 144
Study 30558396 — intervention group
Group type: COMPARATOR
Intervention: Comparison between CED and MED
Number of subjects: 144
Study 29906360 — intervention group
Group type: EXPERIMENTAL
Intervention: rehabilitation exercises
Number of subjects: 44
Study 29906360 — intervention group
Group type: EXPERIMENTAL
Intervention: manual lymphatic drainage
Number of subjects: 44
Study 29906360 — intervention group
Group type: EXPERIMENTAL
Intervention: pneumatic compression pump
Number of subjects: 44
Study 29906360 — intervention group
Group type: EXPERIMENTAL
Intervention: education only
Number of subjects: 44
Study 24526709 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS over the contralesional pars triangularis (PTr) for 10 sessions
Number of subjects: 56
Study 24526709 — intervention group
Group type: COMPARATOR
Intervention: Sham 1-Hz stimulation
Number of subjects: 56
Study 23253701 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-intensity warfarin (INR 2.1 to 2.5)
Number of subjects: 786
Study 23253701 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin (INR 1.6 to 2.0)
Number of subjects: 786
Study 23253701 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (200 mg per day)
Number of subjects: 786
Study 23253701 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-intensity warfarin
Number of subjects: 786
Study 23253701 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin
Number of subjects: 786
Study 23253701 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 786
Study 23253701 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 786
Study 20093151 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolutely correct condition (100% correct)
Number of subjects: 64
Study 20093151 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly correct condition (80% correct)
Number of subjects: 64
Study 20093151 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly incorrect condition (20% correct)
Number of subjects: 64
Study 20093151 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally incorrect condition (0% correct)
Number of subjects: 64
Study 20093151 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct items
Number of subjects: 64
Study 20093151 — intervention group
Group type: EXPERIMENTAL
Intervention: Replaced items (related stimuli)
Number of subjects: 64
Study 18338277 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (with superficial heat and exercise)
Number of subjects: 45
Study 18338277 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (US) (with superficial heat and exercise)
Number of subjects: 45
Study 18338277 — intervention group
Group type: COMPARATOR
Intervention: Control group (superficial heat and exercise)
Number of subjects: 45
Study 15693730 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 139
Study 15693730 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 139
Study 12854696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleaning intervention in uncarpeted homes
Number of subjects: 39
Study 12854696 — intervention group
Group type: COMPARATOR
Intervention: Cleaning intervention in carpeted homes
Number of subjects: 39
Study 12854696 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis for uncarpeted homes
Number of subjects: 39
Study 12854696 — intervention group
Group type: COMPARATOR
Intervention: Correlation analysis for carpeted homes
Number of subjects: 39
Study 12854696 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression model including confounding variables
Number of subjects: 39
Study 10369553 — intervention group
Group type: EXPERIMENTAL
Intervention: Zemaphyte (traditional Chinese herbal medicine)
Number of subjects: 40
Study 10369553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8899317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ukrain
Number of subjects: 10
Study 8899317 — intervention group
Group type: COMPARATOR
Intervention: Control (no Ukrain)
Number of subjects: 10
Study 1930859 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 50 mg/day
Number of subjects: 10
Study 1930859 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (NIF) 90 mg/day
Number of subjects: 10
Study 1930859 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 10
Study 3911962 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen suppositories
Number of subjects: 120
Study 3911962 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol suppositories
Number of subjects: 120
Study 3911962 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 120
Study 29953986 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography monitoring
Number of subjects: 185
Study 29953986 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring including pulse oximetry (Control)
Number of subjects: 185
Study 26992096 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (ARB)
Number of subjects: 60
Study 26992096 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (CCB)
Number of subjects: 60
Study 25509939 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic TB infected females
Number of subjects: 67
Study 25509939 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic TB infected females on ATT
Number of subjects: 67
Study 25509939 — intervention group
Group type: COMPARATOR
Intervention: Control females
Number of subjects: 67
Study 24397109 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (GCSF); dosage and duration not specified.
Number of subjects: 0
Study 21564441 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 36
Study 21564441 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day
Number of subjects: 36
Study 18492831 — intervention group
Group type: EXPERIMENTAL
Intervention: 50:50 glucose:fructose
Number of subjects: 6
Study 18492831 — intervention group
Group type: EXPERIMENTAL
Intervention: 25:75 glucose:fructose
Number of subjects: 6
Study 18492831 — intervention group
Group type: COMPARATOR
Intervention: 100:0 glucose
Number of subjects: 6
Study 16804018 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented papaya preparation 9 g/day
Number of subjects: 54
Study 16804018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 12654667 — intervention group
Group type: EXPERIMENTAL
Intervention: 1263W94 (50 to 1,600 mg)
Number of subjects: 30
Study 12654667 — intervention group
Group type: EXPERIMENTAL
Intervention: 1263W94 (100 to 1,600 mg)
Number of subjects: 30
Study 12654667 — intervention group
Group type: EXPERIMENTAL
Intervention: 1263W94
Number of subjects: 30
Study 12654667 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal
Number of subjects: 30
Study 10767192 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue ultrasonography
Number of subjects: 31
Study 8634929 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 300mg intravenously (i.v.) q6h
Number of subjects: 40
Study 8634929 — intervention group
Group type: COMPARATOR
Intervention: Heater probe thermocoagulation therapy and cimetidine 300mg i.v. q6h
Number of subjects: 40
Study 8634929 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40mg intravenous bolus initially followed by 40mg i.v. qd
Number of subjects: 40
Study 8634929 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40mg intravenous bolus initially followed by 40mg i.v. q12h
Number of subjects: 40
Study 1473431 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam-beta-cyclodextrin (20 mg/day for 14 days)
Number of subjects: 64
Study 1473431 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Piroxicam (20 mg/day for 14 days)
Number of subjects: 64
Study 1473431 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg/day for 14 days)
Number of subjects: 64
Study 1473431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 6439693 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose alone
Number of subjects: 3
Study 6439693 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose plus fat emulsion (3:1 mixture)
Number of subjects: 3
Study 31220933 — intervention group
Group type: EXPERIMENTAL
Intervention: Child support group (children engaged in supportive behavior 2 days/week)
Number of subjects: 102
Study 31220933 — intervention group
Group type: COMPARATOR
Intervention: Control group (no enrolled child support)
Number of subjects: 102
Study 31220933 — intervention group
Group type: EXPERIMENTAL
Intervention: Child support group
Number of subjects: 102
Study 31220933 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 102
Study 29930520 — intervention group
Group type: EXPERIMENTAL
Intervention: LIFESTYLE psychosocial group intervention
Number of subjects: 420
Study 29930520 — intervention group
Group type: COMPARATOR
Intervention: Brief educational group intervention
Number of subjects: 420
Study 27348905 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive group (acupoint embedding + forlax)
Number of subjects: 150
Study 27348905 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint embedding group
Number of subjects: 150
Study 27348905 — intervention group
Group type: COMPARATOR
Intervention: Forlax group
Number of subjects: 150
Study 24995756 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement pharmacotherapy (6-week regimen)
Number of subjects: 424
Study 24995756 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nicotine replacement therapy)
Number of subjects: 424
Study 22828172 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT‐T
Number of subjects: 60
Study 22828172 — intervention group
Group type: COMPARATOR
Intervention: Information-only
Number of subjects: 60
Study 20141732 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated traditional Chinese medicine therapy and chemotherapy
Number of subjects: 95
Study 20141732 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (control group)
Number of subjects: 95
Study 17394179 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-tumor necrosis factor alpha (anti-TNFalpha) therapy
Number of subjects: 68
Study 17394179 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-DVU score
Number of subjects: 68
Study 17394179 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 68
Study 15826418 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood re-infusion units
Number of subjects: 50
Study 15826418 — intervention group
Group type: COMPARATOR
Intervention: Vacuum drains
Number of subjects: 50
Study 12014695 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg/kg)
Number of subjects: 26
Study 12014695 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide and oxygen (30%/70%)
Number of subjects: 26
Study 9921385 — intervention group
Group type: EXPERIMENTAL
Intervention: High school driver education courses
Number of subjects: 9
Study 9921385 — intervention group
Group type: COMPARATOR
Intervention: Availability of high school driver education courses
Number of subjects: 9
Study 7784683 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intrathecal anesthesia with 10 mg hyperbaric bupivacaine (Group 1)
Number of subjects: 45
Study 7784683 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intrathecal anesthesia with 10 mg hyperbaric bupivacaine and 25 mcg fentanyl (Group 2)
Number of subjects: 45
Study 7784683 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intrathecal dose of 15 mg hyperbaric bupivacaine (Group 3)
Number of subjects: 45
Study 2113756 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (30 mg/day)
Number of subjects: 20
Study 2113756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 474476 — intervention group
Group type: EXPERIMENTAL
Intervention: 11.5 mg zinc daily
Number of subjects: 67
Study 474476 — intervention group
Group type: COMPARATOR
Intervention: 14.7 mg zinc daily
Number of subjects: 67
Study 474476 — intervention group
Group type: COMPARATOR
Intervention: Nutrition survey (no specific intervention mentioned)
Number of subjects: 67
Study 474476 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 67
Study 31041683 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy alone (ET)
Number of subjects: 3746
Study 31041683 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus endocrine therapy (ET + C)
Number of subjects: 3746
Study 28286842 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl prednisolone (MP)
Number of subjects: 68
Study 28286842 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM)
Number of subjects: 68
Study 26417998 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative fractional Er:YAG laser (AFR)
Number of subjects: 34
Study 26417998 — intervention group
Group type: COMPARATOR
Intervention: Nonablative fractional 1550-nm Er:glass laser (NAFR)
Number of subjects: 34
Study 23359344 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabalumab 30 mg
Number of subjects: 0
Study 23359344 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabalumab 60 mg
Number of subjects: 0
Study 23359344 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabalumab 160 mg
Number of subjects: 0
Study 23359344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23359344 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabalumab (all doses combined)
Number of subjects: 0
Study 20888709 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + cisplatin (20 mg/m² weekly)
Number of subjects: 308
Study 20888709 — intervention group
Group type: COMPARATOR
Intervention: RT (70 Gy at 1.8-2 Gy/day)
Number of subjects: 308
Study 19210767 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized tinnitus care group
Number of subjects: 198
Study 19210767 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 198
Study 16551158 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth‐Nominated Support Team‐Version 1 (YST‐1) plus treatment-as-usual
Number of subjects: 289
Study 16551158 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual only
Number of subjects: 289
Study 12657073 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care protocol with preoperative home visits by a nurse and physical therapist, and fewer postoperative visits (9-12 visits)
Number of subjects: 136
Study 12657073 — intervention group
Group type: COMPARATOR
Intervention: Existing home care protocol (11-47 visits)
Number of subjects: 136
Study 10607685 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN) therapy
Number of subjects: 54
Study 9106647 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide (100 mg given twice daily for 5 days)
Number of subjects: 155
Study 9106647 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemotherapy (cisplatin and etoposide alternating with cyclophosphamide, doxorubicin, and vincristine)
Number of subjects: 155
Study 9106647 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide
Number of subjects: 155
Study 9106647 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemotherapy
Number of subjects: 155
Study 8459986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron plus dexamethasone (0.15 mg/kg i.v. x 3 and 20 mg i.v.)
Number of subjects: 289
Study 8459986 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide plus dexamethasone (3 mg/kg i.v. x 2 and 20 mg i.v.)
Number of subjects: 289
Study 8459986 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 289
Study 2429120 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemongrass (abafado)
Number of subjects: 68
Study 29910012 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-rated alliance
Number of subjects: 123
Study 29910012 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-rated alliance
Number of subjects: 123
Study 29910012 — intervention group
Group type: EXPERIMENTAL
Intervention: Task component of alliance
Number of subjects: 123
Study 29910012 — intervention group
Group type: EXPERIMENTAL
Intervention: Task and goal components of alliance
Number of subjects: 123
Study 29910012 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist alliance
Number of subjects: 123
Study 27496700 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Goal intervention (Goal Attainment Scaling)
Number of subjects: 66
Study 24754070 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Idrinol 1000 mg/day for 10-14 days (Group 1)
Number of subjects: 60
Study 24754070 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy of coronary heart disease (Group 2)
Number of subjects: 60
Study 22642473 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus
Number of subjects: 300
Study 22642473 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 300
Study 20025892 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory trains of transcranial magnetic stimulation (rTMS) of the right parietal cortex
Number of subjects: 0
Study 20025892 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory trains of transcranial magnetic stimulation (rTMS) of the left parietal cortex
Number of subjects: 0
Study 20025892 — intervention group
Group type: COMPARATOR
Intervention: Control (no rTMS)
Number of subjects: 0
Study 18449096 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD group
Number of subjects: 20
Study 18449096 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 20
Study 15651171 — intervention group
Group type: EXPERIMENTAL
Intervention: oblimersen plus dacarbazine
Number of subjects: 14
Study 15651171 — intervention group
Group type: COMPARATOR
Intervention: dacarbazine alone
Number of subjects: 14
Study 9158082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 15
Study 7954025 — intervention group
Group type: EXPERIMENTAL
Intervention: rt‐PA
Number of subjects: 115
Study 7954025 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 115
Study 3595364 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrugated latex drain
Number of subjects: 60
Study 3595364 — intervention group
Group type: COMPARATOR
Intervention: No drain (control)
Number of subjects: 60
Study 28865098 — intervention group
Group type: EXPERIMENTAL
Intervention: Acotiamide 300 mg/day + rabeprazole 10 mg/day
Number of subjects: 0
Study 28865098 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 20 mg/day
Number of subjects: 0
Study 27982344 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 61
Study 27982344 — intervention group
Group type: EXPERIMENTAL
Intervention: Late open lung strategy (L-OLS)
Number of subjects: 61
Study 27982344 — intervention group
Group type: EXPERIMENTAL
Intervention: Early open lung strategy (E-OLS)
Number of subjects: 61
Study 25912391 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided stent implantation
Number of subjects: 230
Study 25912391 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided stent implantation
Number of subjects: 230
Study 23688323 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg) administered subcutaneously once weekly for 12 weeks
Number of subjects: 104
Study 23688323 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered subcutaneously once weekly for 12 weeks
Number of subjects: 104
Study 23688323 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg)
Number of subjects: 104